{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:59:18Z","timestamp":1785308358860,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Startup Fund for Scientific Research, Fujian Medical University","award":["2020QH1061"],"award-info":[{"award-number":["2020QH1061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00066-024-02242-6","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T06:02:28Z","timestamp":1717394548000},"page":"805-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China"],"prefix":"10.1007","volume":"200","author":[{"given":"Shaohong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-5281","authenticated-orcid":false,"given":"Xiuhua","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"1","key":"2242_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12943-019-0950-1","volume":"18","author":"H Zhuang","year":"2019","unstructured":"Zhuang\u00a0H, Shi\u00a0S, Yuan\u00a0Z et\u00a0al (2019) Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer 18(1):21. https:\/\/doi.org\/10.1186\/s12943-019-0950-1","journal-title":"Mol Cancer"},{"issue":"4","key":"2242_CR2","doi-asserted-by":"publisher","first-page":"e7603","DOI":"10.7759\/cureus.7603","volume":"12","author":"S Munier","year":"2020","unstructured":"Munier\u00a0S, Ginalis\u00a0EE, Patel\u00a0NV et\u00a0al (2020) Radiation necrosis in intracranial lesions. Cureus 12(4):e7603. https:\/\/doi.org\/10.7759\/cureus.7603","journal-title":"Cureus"},{"issue":"8","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-019-0818-y","volume":"21","author":"FS Ali","year":"2019","unstructured":"Ali\u00a0FS, Arevalo\u00a0O, Zorofchian\u00a0S et\u00a0al (2019) Cerebral radiation necrosis: incidence, pathogenesis, diagnostic challenges, and future opportunities. Curr Oncol Rep 21(8):66. https:\/\/doi.org\/10.1007\/s11912-019-0818-y","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2242_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jocn.2012.09.011","volume":"20","author":"G Rahmathulla","year":"2013","unstructured":"Rahmathulla\u00a0G, Marko\u00a0NF, Weil\u00a0RJ (2013) Cerebral radiation necrosis: a\u00a0review of the pathobiology, diagnosis and management considerations. J\u00a0Clin Neurosci 20(4):485\u2013502. https:\/\/doi.org\/10.1016\/j.jocn.2012.09.011","journal-title":"J Clin Neurosci"},{"issue":"3 Suppl","key":"2242_CR5","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijrobp.2009.02.091","volume":"76","author":"YR Lawrence","year":"2010","unstructured":"Lawrence\u00a0YR, Li\u00a0XA, el Naqa\u00a0I et\u00a0al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20\u2013S27. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.091","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1\u20132","key":"2242_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000506777","volume":"106","author":"P Zhang","year":"2021","unstructured":"Zhang\u00a0P, Cao\u00a0Y, Chen\u00a0S et\u00a0al (2021) Combination of vinpocetine and dexamethasone alleviates cognitive impairment in nasopharyngeal carcinoma patients following radiation injury. Pharmacology 106(1\u20132):37\u201344. https:\/\/doi.org\/10.1159\/000506777","journal-title":"Pharmacology"},{"key":"2242_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.steroids.2015.06.015","volume":"102","author":"CL Jiang","year":"2015","unstructured":"Jiang\u00a0CL, Liu\u00a0L, Li\u00a0Z et\u00a0al (2015) The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. Steroids 102:27\u201331. https:\/\/doi.org\/10.1016\/j.steroids.2015.06.015","journal-title":"Steroids"},{"issue":"8","key":"2242_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot\u00a0OL, Wick\u00a0W, Mason\u00a0W et\u00a0al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N\u00a0Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"28","key":"2242_CR9","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman\u00a0HS, Prados\u00a0MD, Wen\u00a0PY et\u00a0al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J\u00a0Clin Oncol 27(28):4733\u20134740. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"issue":"20","key":"2242_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick\u00a0W, Gorlia\u00a0T, Bendszus\u00a0M et\u00a0al (2017) Lomustine and bevacizumab in progressive glioblastoma. N\u00a0Engl J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"issue":"4","key":"2242_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ijrobp.2017.12.257","volume":"100","author":"R Yang","year":"2018","unstructured":"Yang\u00a0R, Duan\u00a0C, Yuan\u00a0L et\u00a0al (2018) Inhibitors of HIF-1alpha and CXCR4 mitigate the development of radiation necrosis in mouse brain. Int J Radiat Oncol Biol Phys 100(4):1016\u20131025. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.257","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2242_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ijrobp.2018.04.068","volume":"101","author":"Y Xu","year":"2018","unstructured":"Xu\u00a0Y, Rong\u00a0X, Hu\u00a0W et\u00a0al (2018) Bevacizumab monotherapy reduces radiation-induced brain necrosis in nasopharyngeal carcinoma patients: a\u00a0randomized controlled trial. Int J Radiat Oncol Biol Phys 101(5):1087\u20131095. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.068","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2242_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors\u00a0LB, Portnow\u00a0J, Ahluwalia\u00a0M et\u00a0al (2020) Central nervous system cancers, version\u00a03.2020, NCCN clinical practice guidelines in oncology. J\u00a0Natl Compr Canc Netw 18(11):1537\u20131570. https:\/\/doi.org\/10.6004\/jnccn.2020.0052","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2242_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00066-022-01973-8","volume":"198","author":"D Bernhardt","year":"2022","unstructured":"Bernhardt\u00a0D, Konig\u00a0L, Grosu\u00a0AL et\u00a0al (2022) DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. Strahlenther Onkol 198(11):971\u2013980. https:\/\/doi.org\/10.1007\/s00066-022-01973-8","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"2242_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3760\/cma.j.issn.1671-8925.2019.06.001","volume":"18","author":"Chinese Multidisciplinary Collaboration Group of Radiation-induced Brain Injury SCPBoBaSCI","year":"2019","unstructured":"Chinese Multidisciplinary Collaboration Group of Radiation-induced Brain Injury SCPBoBaSCI (2019) Neurology branch of Chinese medical doctor assciation. Diagnoses and treatments of radiation-induced brain injury: an expert consensus. Chin J Neuromed 18(6):541\u2013549. https:\/\/doi.org\/10.3760\/cma.j.issn.1671-8925.2019.06.001","journal-title":"Chin J Neuromed"},{"key":"2242_CR16","doi-asserted-by":"publisher","first-page":"e2100355","DOI":"10.1200\/GO.21.00355","volume":"8","author":"N Gupta","year":"2022","unstructured":"Gupta\u00a0N, Nehra\u00a0P, Chauhan\u00a0AS et\u00a0al (2022) Cost effectiveness of bevacizumab plus chemotherapy for the treatment of advanced and metastatic cervical cancer in India\u2014a model-based economic analysis. Jco Glob Oncol 8:e2100355. https:\/\/doi.org\/10.1200\/GO.21.00355","journal-title":"Jco Glob Oncol"},{"issue":"1","key":"2242_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3892\/ol.2019.11099","volume":"19","author":"Z Chen","year":"2020","unstructured":"Chen\u00a0Z, Zhan\u00a0M, Tian\u00a0F et\u00a0al (2020) Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma. Oncol Lett 19(1):424\u2013430. https:\/\/doi.org\/10.3892\/ol.2019.11099","journal-title":"Oncol Lett"},{"key":"2242_CR18","unstructured":"(2023) Yaozhi data service provider. Drug information inquiry. https:\/\/db.yaozh.com\/yaopinzhongbiao. Accessed 1 May 2023"},{"issue":"4","key":"2242_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","volume":"5","author":"X Wan","year":"2019","unstructured":"Wan\u00a0X, Zhang\u00a0Y, Tan\u00a0C et\u00a0al (2019) First-line nivolumab plus Ipilimumab vs sunitinib for metastatic renal cell carcinoma: a\u00a0cost-effectiveness analysis. JAMA Oncol 5(4):491\u2013496. https:\/\/doi.org\/10.1001\/jamaoncol.2018.7086","journal-title":"JAMA Oncol"},{"issue":"6","key":"2242_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.18553\/jmcp.2018.24.6.514","volume":"24","author":"R Mistry","year":"2018","unstructured":"Mistry\u00a0R, May\u00a0JR, Suri\u00a0G et\u00a0al (2018) Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2-advanced or metastatic breast cancer: a\u00a0U.S. Payer perspective. J\u00a0Manag Care Spec Pharm 24(6):514\u2013523. https:\/\/doi.org\/10.18553\/jmcp.2018.24.6.514","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"2242_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","volume":"33","author":"E Sarnes","year":"2011","unstructured":"Sarnes\u00a0E, Crofford\u00a0L, Watson\u00a0M et\u00a0al (2011) Incidence and US costs of corticosteroid-associated adverse events: a\u00a0systematic literature review. Clin Ther 33(10):1413\u20131432. https:\/\/doi.org\/10.1016\/j.clinthera.2011.09.009","journal-title":"Clin Ther"},{"issue":"4","key":"2242_CR22","doi-asserted-by":"publisher","first-page":"e0196007","DOI":"10.1371\/journal.pone.0196007","volume":"13","author":"W Wong","year":"2018","unstructured":"Wong\u00a0W, Yim\u00a0YM, Kim\u00a0A et\u00a0al (2018) Assessment of costs associated with adverse events in patients with cancer. PLoS ONE 13(4):e196007. https:\/\/doi.org\/10.1371\/journal.pone.0196007","journal-title":"PLoS ONE"},{"issue":"3","key":"2242_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40273-013-0065-2","volume":"32","author":"T Chongqing","year":"2014","unstructured":"Chongqing\u00a0T, Liubao\u00a0P, Xiaohui\u00a0Z et\u00a0al (2014) Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese national comprehensive cancer network (NCCN) clinical practice guidelines in oncology: gastric cancer. PharmacoEconomics 32(3):235\u2013243. https:\/\/doi.org\/10.1007\/s40273-013-0065-2","journal-title":"PharmacoEconomics"},{"issue":"5","key":"2242_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COC.0000000000000671","volume":"43","author":"X Weng","year":"2020","unstructured":"Weng\u00a0X, Huang\u00a0X, Li\u00a0H et\u00a0al (2020) First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a\u00a0cost-effectiveness analysis. Am J Clin Oncol 43(5):340\u2013348. https:\/\/doi.org\/10.1097\/COC.0000000000000671","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2242_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12962-023-00435-x","volume":"21","author":"H Gong","year":"2023","unstructured":"Gong\u00a0H, Ong\u00a0SC, Li\u00a0F et\u00a0al (2023) Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc 21(1):20. https:\/\/doi.org\/10.1186\/s12962-023-00435-x","journal-title":"Cost Eff Resour Alloc"},{"issue":"7","key":"2242_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40261-018-0649-x","volume":"38","author":"B Wu","year":"2018","unstructured":"Wu\u00a0B, Tobe\u00a0RG, Liu\u00a0Y et\u00a0al (2018) Health economic analysis of antiplatelet therapy for acute coronary syndromes in the context of five eastern asian countries. Clin Drug Investig 38(7):621\u2013630. https:\/\/doi.org\/10.1007\/s40261-018-0649-x","journal-title":"Clin Drug Investig"},{"issue":"17","key":"2242_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2217\/fon-2019-0821","volume":"16","author":"PF Zhang","year":"2020","unstructured":"Zhang\u00a0PF, Xie\u00a0D, Li\u00a0Q (2020) Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. Future Oncol 16(17):1189\u20131198. https:\/\/doi.org\/10.2217\/fon-2019-0821","journal-title":"Future Oncol"},{"issue":"27","key":"2242_CR28","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.2217\/fon-2018-0321","volume":"14","author":"J Zhu","year":"2018","unstructured":"Zhu\u00a0J, He\u00a0W, Ye\u00a0M et\u00a0al (2018) Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncol 14(27):2833\u20132840. https:\/\/doi.org\/10.2217\/fon-2018-0321","journal-title":"Future Oncol"},{"issue":"1","key":"2242_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu\u00a0S, Zhang\u00a0Y, Yao\u00a0Y et\u00a0al (2020) Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database. J\u00a0Headache Pain 21(1):53. https:\/\/doi.org\/10.1186\/s10194-020-01117-2","journal-title":"J Headache Pain"},{"issue":"1","key":"2242_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/jdi.12653","volume":"9","author":"B Wu","year":"2018","unstructured":"Wu\u00a0B, Zhang\u00a0S, Lin\u00a0H et\u00a0al (2018) Prevention of renal failure in Chinese patients with newly diagnosed type\u00a02 diabetes: a\u00a0cost-effectiveness analysis. J\u00a0Diabetes Investig 9(1):152\u2013161. https:\/\/doi.org\/10.1111\/jdi.12653","journal-title":"J Diabetes Investig"},{"issue":"12","key":"2242_CR31","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1080\/21645515.2021.1996151","volume":"17","author":"N Jiang","year":"2021","unstructured":"Jiang\u00a0N, Li\u00a0R, Bao\u00a0J et\u00a0al (2021) Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources. Hum Vaccin Immunother 17(12):5638\u20135645. https:\/\/doi.org\/10.1080\/21645515.2021.1996151","journal-title":"Hum Vaccin Immunother"},{"key":"2242_CR32","unstructured":"National bureau of statistics of China. Annual data. http:\/\/www.stats.gov.cn\/english\/Statisticaldata\/AnnualData"},{"issue":"5","key":"2242_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin\u00a0R, de Charro\u00a0F (2001) EQ-5D: a\u00a0measure of health status from the EuroQol group. Ann Med 33(5):337\u2013343. https:\/\/doi.org\/10.3109\/07853890109002087","journal-title":"Ann Med"},{"issue":"4","key":"2242_CR34","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo\u00a0N, Liu\u00a0G, Li\u00a0M et\u00a0al (2017) Estimating an EQ-5D-5L value set for China. Value Health 20(4):662\u2013669. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016","journal-title":"Value Health"},{"issue":"7","key":"2242_CR35","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.7759\/cureus.667","volume":"8","author":"NH Lester-Coll","year":"2016","unstructured":"Lester-Coll\u00a0NH, Dosoretz\u00a0AP, Hayman\u00a0JA et\u00a0al (2016) Health state utilities for patients with brain metastases. Cureus 8(7):e667. https:\/\/doi.org\/10.7759\/cureus.667","journal-title":"Cureus"},{"key":"2242_CR36","unstructured":"Global Burden of Disease Study 2019 (2019) Disability weights. http:\/\/ghdx.healthdata.org\/record\/ihme-data\/gbd-2019-disability-weights"},{"issue":"5","key":"2242_CR37","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees\u00a0B, Lloyd\u00a0AJ, Dewilde\u00a0S et\u00a0al (2017) Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol 13(5):e195\u2013e203. https:\/\/doi.org\/10.1111\/ajco.12477","journal-title":"Asia Pac J Clin Oncol"},{"key":"2242_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees\u00a0B, Stafford\u00a0M, Gavriel\u00a0S et\u00a0al (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6:84. https:\/\/doi.org\/10.1186\/1477-7525-6-84","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2242_CR39","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/j.clbc.2021.01.019","volume":"21","author":"X Huang","year":"2021","unstructured":"Huang\u00a0X, Lin\u00a0S, Rao\u00a0X et\u00a0al (2021) First-line treatment with ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive advanced breast cancer: a\u00a0cost-effectiveness analysis. Clin Breast Cancer 21(4):e479\u2013e488. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.019","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"2242_CR40","doi-asserted-by":"publisher","first-page":"e036107","DOI":"10.1136\/bmjopen-2019-036107","volume":"10","author":"X Huang","year":"2020","unstructured":"Huang\u00a0X, Weng\u00a0X, Lin\u00a0S et\u00a0al (2020) Half-dose fulvestrant plus anastrozole as a\u00a0first-line treatment for hormone receptor-positive metastatic breast cancer: a\u00a0cost-effectiveness analysis. Bmj Open 10(8):e36107. https:\/\/doi.org\/10.1136\/bmjopen-2019-036107","journal-title":"Bmj Open"},{"key":"2242_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19084816","author":"M Zhao","year":"2022","unstructured":"Zhao\u00a0M, Chi\u00a0Z, Pan\u00a0X et\u00a0al (2022) Economic evaluation of nemonoxacin, moxifloxacin and levofloxacin in the treatment of early community-acquired pneumonia with possible pulmonary tuberculosis. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph19084816","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2242_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1478-7547-1-8","volume":"1","author":"R Hutubessy","year":"2003","unstructured":"Hutubessy\u00a0R, Chisholm\u00a0D, Edejer\u00a0TT (2003) Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1(1):8. https:\/\/doi.org\/10.1186\/1478-7547-1-8","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"2242_CR43","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2214-109X(22)00554-X","volume":"11","author":"H Liu","year":"2023","unstructured":"Liu\u00a0H, Li\u00a0R, Zhang\u00a0Y et\u00a0al (2023) Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a\u00a0cost-effectiveness analysis. Lancet Glob Health 11(3):e456\u2013e465. https:\/\/doi.org\/10.1016\/S2214-109X(22)00554-X","journal-title":"Lancet Glob Health"},{"issue":"2","key":"2242_CR44","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","volume":"10","author":"S Su","year":"2022","unstructured":"Su\u00a0S, Wong\u00a0WC, Zou\u00a0Z et\u00a0al (2022) Cost-effectiveness of universal screening for chronic hepatitis\u00a0B virus infection in China: an economic evaluation. Lancet Glob Health 10(2):e278\u2013e287. https:\/\/doi.org\/10.1016\/S2214-109X(21)00517-9","journal-title":"Lancet Glob Health"},{"issue":"20","key":"2242_CR45","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1002\/cncr.32368","volume":"125","author":"X Wan","year":"2019","unstructured":"Wan\u00a0X, Luo\u00a0X, Tan\u00a0C et\u00a0al (2019) First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a\u00a0united s\u2011based cost-effectiveness analysis. Cancer 125(20):3526\u20133534. https:\/\/doi.org\/10.1002\/cncr.32368","journal-title":"Cancer"},{"key":"2242_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.336","author":"L Raez","year":"2021","unstructured":"Raez\u00a0L, Botero\u00a0A, Khan\u00a0A, Izquierdo\u00a0P, Castellon\u00a0I (2021) Brain necrosis in patients with metastatic lung and breast cancer successfully treated with bevacizumab. J\u00a0Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.336","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2242_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.radonc.2016.04.027","volume":"120","author":"XS Wang","year":"2016","unstructured":"Wang\u00a0XS, Ying\u00a0HM, He\u00a0XY et\u00a0al (2016) Treatment of cerebral radiation necrosis with nerve growth factor: a\u00a0prospective, randomized, controlled phase\u00a0II study. Radiother Oncol 120(1):69\u201375. https:\/\/doi.org\/10.1016\/j.radonc.2016.04.027","journal-title":"Radiother Oncol"},{"issue":"1","key":"2242_CR48","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.ijrobp.2010.11.070","volume":"82","author":"TC Lam","year":"2012","unstructured":"Lam\u00a0TC, Wong\u00a0FC, Leung\u00a0TW et\u00a0al (2012) Clinical outcomes of 174 nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. Int J Radiat Oncol Biol Phys 82(1):e57\u2013e65. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.070","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2242_CR49","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1034\/j.1399-6576.2000.440404.x","volume":"44","author":"K Mursch","year":"2000","unstructured":"Mursch\u00a0K, Buhre\u00a0W, Behnke-Mursch\u00a0J (2000) Peroperative cardiovascular stability during brainstem surgery the use of high-dose methylprednisolone compared to dexamethasone a retrospective analysis[J. Acta Anaesthesiol Scand 44(4):378\u2013382. https:\/\/doi.org\/10.1034\/j.1399-6576.2000.440404.x","journal-title":"Acta Anaesthesiol Scand"},{"issue":"07","key":"2242_CR50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.13798\/j.issn.1009-153X.2020.07.010","volume":"25","author":"L Cai","year":"2020","unstructured":"Cai\u00a0L, Xiong\u00a0Z, Li\u00a0J et\u00a0al (2020) Treatment of high-dose methylprednisolone for patients with radiation brain edema[J. Chin J Clin Neurosurg 25(07):443\u2013446. https:\/\/doi.org\/10.13798\/j.issn.1009-153X.2020.07.010","journal-title":"Chin J Clin Neurosurg"},{"key":"2242_CR51","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.eclinm.2022.101618","volume":"52","author":"D Pan","year":"2022","unstructured":"Pan\u00a0D, Rong\u00a0X, Chen\u00a0D et\u00a0al (2022) Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: a\u00a0multicentre, retrospective, registry-based cohort study. EClinicalMedicine 52:101618. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101618","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2242_CR52","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3779\/j.issn.1009-3419.2022.101.18","volume":"25","author":"Y Chen","year":"2022","unstructured":"Chen\u00a0Y, Wang\u00a0X, Bing\u00a0S et\u00a0al (2022) Expert consensus on the treatment of antiangiogenic agents for radiation brain necrosis. Chin J Lung Cancer 25(5):291\u2013294. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2022.101.18","journal-title":"Chin J Lung Cancer"},{"issue":"10","key":"2242_CR53","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-03-0426","volume":"10","author":"RA Nordal","year":"2004","unstructured":"Nordal\u00a0RA, Nagy\u00a0A, Pintilie\u00a0M et\u00a0al (2004) Hypoxia and hypoxia-inducible factor\u20111 target genes in central nervous system radiation injury: a\u00a0role for vascular endothelial growth factor. Clin Cancer Res 10(10):3342\u20133353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0426","journal-title":"Clin Cancer Res"},{"key":"2242_CR54","doi-asserted-by":"publisher","first-page":"4793517","DOI":"10.1155\/2021\/4793517","volume":"2021","author":"X Yang","year":"2021","unstructured":"Yang\u00a0X, Ren\u00a0H, Fu\u00a0J (2021) Treatment of radiation-induced brain necrosis. Oxid Med Cell Longev 2021:4793517. https:\/\/doi.org\/10.1155\/2021\/4793517","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"2242_CR55","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin\u00a0VA, Bidaut\u00a0L, Hou\u00a0P et\u00a0al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487\u20131495. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2242_CR56","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.2147\/OTT.S223258","volume":"12","author":"H Zhuang","year":"2019","unstructured":"Zhuang\u00a0H, Zhuang\u00a0H, Shi\u00a0S et\u00a0al (2019) Ultra-low-dose bevacizumab for cerebral radiation necrosis: a\u00a0prospective phase\u00a0II clinical study. Onco Targets Ther 12:8447\u20138453. https:\/\/doi.org\/10.2147\/OTT.S223258","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2242_CR57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-021-07889-3","volume":"21","author":"M Khan","year":"2021","unstructured":"Khan\u00a0M, Zhao\u00a0Z, Arooj\u00a0S et\u00a0al (2021) Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a\u00a0systematic review & meta-analysis. BMC Cancer 21(1):167. https:\/\/doi.org\/10.1186\/s12885-021-07889-3","journal-title":"BMC Cancer"},{"issue":"31","key":"2242_CR58","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1111\/1759-7714.15106","volume":"14","author":"YC Hua","year":"2023","unstructured":"Hua\u00a0YC, Gao\u00a0DZ, Wang\u00a0KY et\u00a0al (2023) Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy. Thorac Cancer 14(31):3133\u20133139. https:\/\/doi.org\/10.1111\/1759-7714.15106","journal-title":"Thorac Cancer"},{"issue":"1","key":"2242_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","volume":"118","author":"B Vellayappan","year":"2024","unstructured":"Vellayappan\u00a0B, Lim-Fat\u00a0MJ, Kotecha\u00a0R et\u00a0al (2024) A\u00a0systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery and international stereotactic Radiosurgery society recommendations. Int J Radiat Oncol Biol Phys 118(1):14\u201328. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2242_CR60","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/cas.16053","volume":"115","author":"M Gao","year":"2024","unstructured":"Gao\u00a0M et\u00a0al (2024) Can low-dose intravenous bevacizumab be as effective as high-dose bevacizumab for cerebral radiation necrosis? Cancer Sci 115(2):589\u2013599. https:\/\/doi.org\/10.1111\/cas.16053","journal-title":"Cancer Sci"},{"issue":"11","key":"2242_CR61","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1002\/onco.13954","volume":"26","author":"S Lin","year":"2021","unstructured":"Lin\u00a0S, Luo\u00a0S, Gu\u00a0D et\u00a0al (2021) First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a\u00a0U.S.-Based cost-effectiveness analysis. Oncologist 26(11):e2013\u2013e2020. https:\/\/doi.org\/10.1002\/onco.13954","journal-title":"Oncologist"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02242-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:28:10Z","timestamp":1724455690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02242-6","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.\u00a0Luo, S.\u00a0Lai, Y.\u00a0Wu, J.\u00a0Hong, D.\u00a0Lin, S.\u00a0Lin, X.\u00a0Huang, X.\u00a0Xu, and X.\u00a0Weng declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (no. MRCTA, ECFAH of FMU[2020]164-1) and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}